(2S,4R)-N-BOC-4-羟基哌啶-2-羧酸甲酯 | 254882-06-9

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (2S,4R)-N-BOC-4-羟基哌啶-2-羧酸甲酯
• 中文别名: (2S,4R)-4-羟基哌啶-1,2-二羧酸1-叔丁酯2-甲酯；(2S,4R)-4-羟基哌啶-1,2-二羧酸 1-叔丁酯 2-甲酯
• 英文名称: (2S,4R)-methyl 1-(tert-butoxycarbonyl)-4-hydroxypiperidine-2-carboxylate
• 英文别名: 1-(tert-butyl)-2-methyl-(2S,4R)-4-hydroxypiperidine-1,2-dicarboxylate；N-Boc cis 4R-hydroxy-2S-pipecolic acid methyl ester；(rac,cis)-4-hydroxy-piperidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester；(2S,4R)-4-hydroxy-piperidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester；(2S,4R)-N-(tert-butoxycarbonyl)-4-hydroxypiperidine-2-carboxylic acid methyl ester；1-tert-butyl 2-methyl (2S,4R)-4-hydroxypiperidine-1,2-dicarboxylate；1-O-tert-butyl 2-O-methyl (2S,4R)-4-hydroxypiperidine-1,2-dicarboxylate
• CAS: 254882-06-9
• 化学式: C₁₂H₂₁NO₅
• 分子量: 259.302
• InChiKey: RNMVWSAJMIKMDY-BDAKNGLRSA-N

物化性质

• 沸点：
  402.56°C (rough estimate)
• 密度：
  1.182
• 稳定性/保质期：
  遵照规定使用和储存，则不会分解。

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  76.1
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 安全说明：
  S24/25
• WGK Germany：
  3

SDS

Name:	(2S 4R)-N-BOC-4-Hydroxypiperidine-2-Carboxylic Acid Methyl Ester Material Safety Data Sheet
Synonym:	Methyl (2S,4R)-N-BOC-4-Hydroxypiperidine-2-Carboxylate
CAS:	254882-06-9

Section 1 - Chemical Product MSDS Name:(2S 4R)-N-BOC-4-Hydroxypiperidine-2-Carboxylic Acid Methyl Ester Material Safety Data Sheet
Synonym:Methyl (2S,4R)-N-BOC-4-Hydroxypiperidine-2-Carboxylate

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
254882-06-9	(2S,4R)-N-BOC-4-Hydroxypiperidine-2-Ca	95%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Vapors may be heavier than air. They can spread along the ground and collect in low or confined areas. Runoff from fire control or dilution water may cause pollution.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container. Avoid runoff into storm sewers and ditches which lead to waterways. Clean up spills immediately, observing precautions in the Protective Equipment section. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Use with adequate ventilation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 254882-06-9: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Viscous liquid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C12H21NO5
Molecular Weight: 259.30

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not currently available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 254882-06-9 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
(2S,4R)-N-BOC-4-Hydroxypiperidine-2-Carboxylic Acid Methyl Ester - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 254882-06-9: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 254882-06-9 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 254882-06-9 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (2S,4R)-N-BOC-4-羟基哌啶-2-羧酸甲酯 在 吡啶 、 4-二甲氨基吡啶 、 sodium tetrahydroborate 、 sodium methylate 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 生成 1-O-tert-butyl 2-O-methyl (2S,4S)-4-[(2R)-2-hydroxy-3-methoxy-3-oxopropyl]sulfanylpiperidine-1,2-dicarboxylate
  参考文献：
  名称：

  海胆子房中苦味成分pulcherrimine的所有异构体的合成

  摘要：

  全部八个异构体pulcherrimine的，海胆（的原则苦马粪）卵巢已经被合成，从而导致pulcherrimine的绝对构型的修订。合成的Pulcherrimine和2 S异构体在1.0 mM的浓度下具有很高的苦味。

  DOI：

  10.1016/s0040-4039(01)02095-0
• 作为产物：
  描述：

  N-CBZ--L-烯丙基甘氨酸 在 palladium on activated charcoal 氯化亚砜 、 lipase AY₃₀ from Candida rugosa 、 氢气 作用下， 生成 (2S,4R)-N-BOC-4-羟基哌啶-2-羧酸甲酯
  参考文献：
  名称：

  水解酶在合成环状氨基酸中的用途

  摘要：

  描述了具有所有必要结构特征以使其成为用于药物化学的理想支架的几种环状氨基酸的合成。每个合成过程中的关键步骤是使用水解酶来定义手性中心。为了将这些结构单元详细化为更复杂的分子，使用了结晶和不对称氢化来定义进一步的立体中心。

  DOI：

  10.1016/j.tet.2003.10.116

文献信息

• [EN] HETEROCYCLIC COMPOUNDS AND METHODS FOR THEIR USE<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES ET LEURS PROCÉDÉS D'UTILISATION
  申请人：SPINIFEX PHARM PTY LTD

  公开号：WO2013110135A1

  公开（公告）日：2013-08-01

  The present invention relates to heterocyclic compounds useful for antagonising angiotensin II Type 2 (AT2) receptor. More particularly the invention relates to piperidine compounds, compositions containing them and their use in methods of treating or preventing disorders or diseases associated with AT2 receptor function including neuropathic pain, inflammatory pain, conditions associated with neuronal hypersensitivity, impaired nerve conduction velocity, cell proliferation disorders, disorders associated with an imbalance between bone resorption and bone formation and disorders associated with aberrant nerve regeneration.

  本发明涉及用于拮抗血管紧张素II型2（AT2）受体的杂环化合物。更具体地，本发明涉及哌啶化合物，含有它们的组合物以及它们在治疗或预防与AT2受体功能相关的疾病或疾病的方法中的使用，包括神经病性疼痛、炎症性疼痛、与神经元过敏、神经传导速度受损、细胞增殖紊乱、骨吸收和骨形成之间失衡以及与异常神经再生相关的疾病。
• Novel diazepan derivatives
  申请人：Aebi Johannes

  公开号：US20070249589A1

  公开（公告）日：2007-10-25

  The invention is concerned with novel diazepan derivatives of formula (I) wherein A, X, R 3 , R 4 , R 5 , R 6 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , m and n are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR-2 receptor, CCR-5 receptor and/or CCR-3 receptor and can be used as medicaments.

  这项发明涉及式（I）的新型二氮杂环己烷衍生物，其中A、X、R3、R4、R5、R6、R8、R9、R10、R11、R12、R13、m和n的定义如描述和索赔中所述，以及其生理上可接受的盐。这些化合物是CCR-2受体、CCR-5受体和/或CCR-3受体的拮抗剂，可用作药物。
• [EN] TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS<br/>[FR] COMPOSÉS TRIAZOLOPYRIDINE COMME INHIBITEURS DE LA PIM KINASE
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2010022076A1

  公开（公告）日：2010-02-25

  Compounds of Formula (I), in which A, B, R1, R1a, R2, R3, R4, R5, R6, and R7 have the meanings given in the specification, are receptor tyrosine inhibitors useful in the treatment of immune cell-associated diseases and disorders, such as inflammatory and autoimmune diseases.

  公式（I）的化合物，其中A、B、R1、R1a、R2、R3、R4、R5、R6和R7的含义如规范中所述，是在治疗免疫细胞相关疾病和紊乱方面有用的受体酪氨酸激酶抑制剂，例如炎症性和自身免疫疾病。
• Inhibitors of DNA Methyltransferase
  申请人：Wahhab Amal

  公开号：US20080132525A1

  公开（公告）日：2008-06-05

  The invention relates to the inhibition of DNA methyltransferase isoforms DNMT1 and DNMT3b2. The invention provides compounds and methods for inhibiting DNMT1 and DNMT3b2.

  这项发明涉及抑制DNA甲基转移酶亚型DNMT1和DNMT3b2。该发明提供了用于抑制DNMT1和DNMT3b2的化合物和方法。
• [EN] PDD AND BPD COMPOUNDS<br/>[FR] COMPOSÉS DDP ET BPD
  申请人：FEMTOGENIX LTD

  公开号：WO2016198869A1

  公开（公告）日：2016-12-15

  The invention relates to pyrridinobenzodiazepines (PDDs) comprising three fused 6-7- 6–membered rings and to benzopyrridodiazecines (BPDs) comprising three fused 6-8- 6–membered rings and, in particular, to PDD or BPD dimers linked together or PDD and BPD monomers linked to aromatic groups, and pharmaceutically acceptable salts thereof, which are useful as medicaments, such as anti-proliferative agents. PDDs and BPDs may be represented by formula (I): and salts or solvates thereof, wherein R2, R4-R6 and R8 are independently selected substituent groups; and either: (i) R9 and R10 together form a double bond; (ii) R9 is H and R10 is OH; or (iii) R9 is H and R10 is ORA and RA is C1-6 alkyl; wherein each of m, n, u and w may be 0 or 1; where (a) the compound is a dimer with each monomer being the same or different and being of formula (I) where one of R1, R2, R3 and R7 of the first monomer and one of R'1, R'2, R3 and R'7 of the second monomer form together a bridge having the formula –X-L-X'- linking the monomers and m + n + u + w = 1; or (b) a dimer and one of R1, R2 and R3 of the first monomer and one of R'1, R'2 and R3 of the second monomer form together a bridge having the formula –X-L-X'- linking the monomers and m = n = u = w = o; or (c) one of R1, R2, R3 and R7 has the formula: –X- L-X'-D or -(CH2)f-O-R14 and m + n + u + w = o or 1; or (d) R7 has the formula: –X-L-X'- D or -(CH2)g-O -15 and m + n + u + w = 1; and X-L-X'- is a linker group and D has the formula (II) or (III):

  该发明涉及到包含三个融合的6-7-6环的吡啶苯二氮杂环己烷（PDDs）以及包含三个融合的6-8-6环的苯基吡啶二氮杂环己烷（BPDs），特别是涉及到连接在一起的PDD或BPD二聚体或连接到芳香基团的PDD和BPD单体，以及其药用可接受盐，这些化合物可用作药物，如抗增殖剂。PDDs和BPDs可以用以下公式（I）表示：以及其盐或溶剂化合物，其中R2、R4-R6和R8是独立选择的取代基团；并且：（i）R9和R10共同形成双键；（ii）R9为H且R10为OH；或（iii）R9为H且R10为ORA，RA为C1-6烷基；其中m、n、u和w中的每个可能为0或1；其中（a）该化合物是一个二聚体，每个单体相同或不同且为公式（I）的其中一个，其中第一个单体的R1、R2、R3和R7中的一个和第二个单体的R'1、R'2、R3和R'7中的一个共同形成具有公式-X-L-X'-的桥连接单体，且m + n + u + w = 1；或（b）一个二聚体，第一个单体的R1、R2和R3中的一个和第二个单体的R'1、R'2和R3中的一个共同形成具有公式-X-L-X'-的桥连接单体，且m = n = u = w = o；或（c）R1、R2、R3和R7中的一个具有以下公式：-X-L-X'-D或-(CH2)f-O-R14，且m + n + u + w = o或1；或（d）R7具有以下公式：-X-L-X'-D或-(CH2)g-O-15，且m + n + u + w = 1；而X-L-X'-是一个连接基团，D具有以下公式（II）或（III）。